ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013680" target="_blank" >RIV/00023736:_____/24:00013680 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/24:10486192 RIV/00216208:11320/24:10486192
Result on the web
<a href="https://doi.org/10.1152/ajpcell.00188.2024" target="_blank" >https://doi.org/10.1152/ajpcell.00188.2024</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1152/ajpcell.00188.2024" target="_blank" >10.1152/ajpcell.00188.2024</a>

Result language
angličtina
Original language name
ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells
Original language description
Clinical experience with tyrosine kinase inhibitors (TKIs) over the past two decades has shown that, despite the apparent therapeutic benefit, nearly 30% of patients with chronic myelogenous leukemia (CML) display primary resistance or intolerance to TKIs, and approximately 25% of those treated are forced to switch TKIs at least once during therapy due to acquired resistance. Safe and effective treatment modalities targeting leukemic clones that escape TKI therapy could hence be game changers in the professional management of these patients. Here, we aimed to investigate the efficacy of a novel therapeutic oligonucleotide of unconventional design, called ASP210, to reduce BCR-ABL1 mRNA levels in TKI-resistant CML cells, with the assumption of inducing their apoptosis.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)